CRDF Cardiff Oncology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CRDF matters now
Cardiff Oncology, Inc. (CRDF) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.33 with +0.76% on the session and $90.9M in market capitalization; recent performance reads 1-month -31.25% and YTD -56.94%.
The latest financial table shown here is Q1 2026, with revenue of $41.0K, net income of $-12.3M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.3%.
The latest indexable market news headline is "Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes PACE GARY W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.38
P/S
157.58
EV/EBITDA
-1.71
DCF Value
$0.02
FCF Yield
-45.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2105.7%
Operating Margin
-9033.9%
Net Margin
-8526.1%
ROE
-95.5%
ROA
-91.0%
ROIC
-134.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $41.0K | $-12.3M | $-0.18 |
| Q4 2025 | $243.0K | $-7.2M | $-0.11 |
| FY 2025 | $593.0K | $-45.9M | $-0.69 |
| Q3 2025 | $120.0K | $-11.3M | $-0.17 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.38
Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.